Literature DB >> 20464061

Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality.

Einor Ben Assayag1, Shani Shenhar-Tsarfaty, Keren Ofek, Lilach Soreq, Irena Bova, Ludmila Shopin, Ronan M G Berg, Shlomo Berliner, Itzhak Shapira, Natan M Bornstein, Hermona Soreq.   

Abstract

To date there is no diagnostic biomarker for mild stroke, although elevation of inflammatory biomarkers has been reported at early stages. Previous studies implicated acetylcholinesterase (AChE) involvement in stroke, and circulating AChE activity reflects inflammatory response, since acetylcholine suppresses inflammation. Therefore, carriers of polymorphisms that modify cholinergic activity should be particularly susceptible to inflammatory damage. Our study sought diagnostic values of AChE and Cholinergic Status (CS, the total capacity for acetylcholine hydrolysis) in suspected stroke patients. For this purpose, serum cholinesterase activities, butyrylcholinesterase-K genotype and inflammatory biomarkers were determined in 264 ischemic stroke patients and matched controls during the acute phase. AChE activities were lower (P<0.001), and butyrylcholinesterase activities were higher in patients than in controls (P=0.004). When normalized to sampling time from stroke occurrence, both cholinergic parameters were correlated with multiple inflammatory biomarkers, including fibrinogen, interleukin-6 and C-reactive protein (r=0.713, r=0.607; r=0.421, r=0.341; r=0.276, r=0.255; respectively; all P values<0.001). Furthermore, very low AChE activities predicted subsequent nonsurvival (P=0.036). Also, carriers of the unstable butyrylcholinesterase-K variant were more abundant among patients than controls, and showed reduced activity (P<0.001). Importantly, a cholinergic score combining the two cholinesterase activities discriminated between 94.3% matched pairs of patients and controls, compared with only 75% for inflammatory measures. Our findings present the power of circulation cholinesterase measurements as useful early diagnostic tools for the occurrence of stroke. Importantly, these were considerably more distinctive than the inflammatory biomarkers, albeit closely associated with them, which may open new venues for stroke diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20464061      PMCID: PMC2896466          DOI: 10.2119/molmed.2010.00015

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  29 in total

1.  [Rapid physiological coagulation method in determination of fibrinogen].

Authors:  A CLAUSS
Journal:  Acta Haematol       Date:  1957-04       Impact factor: 2.195

2.  Neuroprotective effect of donepezil, a nicotinic acetylcholine-receptor activator, on cerebral infarction in rats.

Authors:  Minoru Fujiki; Hidenori Kobayashi; Susumu Uchida; Ryo Inoue; Keisuke Ishii
Journal:  Brain Res       Date:  2005-05-10       Impact factor: 3.252

3.  DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites.

Authors:  C F Bartels; F S Jensen; O Lockridge; A F van der Spek; H M Rubinstein; T Lubrano; B N La Du
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

4.  Recommendation of measurement of erythrocyte sedimentation rate of human blood.

Authors: 
Journal:  Am J Clin Pathol       Date:  1977-10       Impact factor: 2.493

Review 5.  Myasthenia gravis: myasthenia vs. cholinergic crisis.

Authors:  Kelly A Hetherington; Joseph D Losek
Journal:  Pediatr Emerg Care       Date:  2005-08       Impact factor: 1.454

6.  Acute stress facilitates long-lasting changes in cholinergic gene expression.

Authors:  D Kaufer; A Friedman; S Seidman; H Soreq
Journal:  Nature       Date:  1998-05-28       Impact factor: 49.962

7.  Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients.

Authors:  Mario Di Napoli; Francesca Papa
Journal:  Stroke       Date:  2002-07       Impact factor: 7.914

8.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

9.  Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation.

Authors:  Hong Wang; Man Yu; Mahendar Ochani; Carol Ann Amella; Mahira Tanovic; Seenu Susarla; Jian Hua Li; Haichao Wang; Huan Yang; Luis Ulloa; Yousef Al-Abed; Christopher J Czura; Kevin J Tracey
Journal:  Nature       Date:  2002-12-22       Impact factor: 49.962

10.  Leukocyte count predicts outcome after ischemic stroke: the Northern Manhattan Stroke Study.

Authors:  Mitchell S V Elkind; Jianfeng Cheng; Tanja Rundek; Bernadette Boden-Albala; Ralph L Sacco
Journal:  J Stroke Cerebrovasc Dis       Date:  2004 Sep-Oct       Impact factor: 2.136

View more
  38 in total

1.  Quantum dot labeling of butyrylcholinesterase maintains substrate and inhibitor interactions and cell adherence features.

Authors:  Nir Waiskopf; Itzhak Shweky; Itai Lieberman; Uri Banin; Hermona Soreq
Journal:  ACS Chem Neurosci       Date:  2010-12-14       Impact factor: 4.418

2.  Different sensitivities of rat skeletal muscles and brain to novel anti-cholinesterase agents, alkylammonium derivatives of 6-methyluracil (ADEMS).

Authors:  Konstantin A Petrov; Lilia O Yagodina; Guzel R Valeeva; Natalya I Lannik; Alexandra D Nikitashina; Albert A Rizvanov; Vladimir V Zobov; Ellya A Bukharaeva; Vladimir S Reznik; Eugeny E Nikolsky; František Vyskočil
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

3.  Decline in serum cholinesterase activities predicts 2-year major adverse cardiac events.

Authors:  Yaron Arbel; Shani Shenhar-Tsarfaty; Nir Waiskopf; Ariel Finkelstein; Amir Halkin; Miri Revivo; Shlomo Berliner; Itzhak Herz; Itzhak Shapira; Gad Keren; Hermona Soreq; Shmuel Banai
Journal:  Mol Med       Date:  2014-02-12       Impact factor: 6.354

Review 4.  Cholinesterases as biomarkers for parasympathetic dysfunction and inflammation-related disease.

Authors:  Shani Shenhar-Tsarfaty; Shlomo Berliner; Natan M Bornstein; Hermona Soreq
Journal:  J Mol Neurosci       Date:  2013-11-20       Impact factor: 3.444

5.  Exosomes Secreted by Adipose-Derived Stem Cells Contribute to Angiogenesis of Brain Microvascular Endothelial Cells Following Oxygen-Glucose Deprivation In Vitro Through MicroRNA-181b/TRPM7 Axis.

Authors:  Yujia Yang; Yue Cai; Yuan Zhang; Juan Liu; Zhiqiang Xu
Journal:  J Mol Neurosci       Date:  2018-04-29       Impact factor: 3.444

6.  Correlations between cholinesterase activity and cognitive scores in post-ischemic rats and patients with vascular dementia.

Authors:  Yan Xiao; Zhi-Zhong Guan; Chang-Xue Wu; Yi Li; Shi-Xiang Kuang; Jin-Jing Pei
Journal:  Cell Mol Neurobiol       Date:  2011-11-17       Impact factor: 5.046

Review 7.  Towards the identification of blood biomarkers for acute stroke in humans: a comprehensive systematic review.

Authors:  Nazeeha Hasan; Peter McColgan; Paul Bentley; Robert J Edwards; Pankaj Sharma
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

8.  Plasma butyrylcholinesterase regulates ghrelin to control aggression.

Authors:  Vicky Ping Chen; Yang Gao; Liyi Geng; Robin J Parks; Yuan-Ping Pang; Stephen Brimijoin
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

9.  Plasma acetylcholinesterase activity correlates with intracerebral β-amyloid load.

Authors:  Adi Alkalay; Gil D Rabinovici; Gabriel Zimmerman; Neha Agarwal; Daniela Kaufer; Bruce L Miller; William J Jagust; Hermona Soreq
Journal:  Curr Alzheimer Res       Date:  2013-01       Impact factor: 3.498

10.  Preclinical studies on neurobehavioral and neuromuscular effects of cocaine hydrolase gene therapy in mice.

Authors:  Vishakantha Murthy; Yang Gao; Liyi Geng; Nathan LeBrasseur; Thomas White; Stephen Brimijoin
Journal:  J Mol Neurosci       Date:  2013-10-02       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.